Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Keith L. Ligon, MD, PhD, is director of the Center for Patient Derived Models (CPDM). He is an associate professor of Pathology at Harvard Medical School with joint appointments at Dana-Farber, the Broad Institute of Harvard and MIT, and Brigham and Women’s Hospital (BWH). He is chief of Neuropathology at Brigham and Women’s Hospital. His research and clinical activities have improved the scientific understanding of brain tumors.
Advances in our ability to make cancer models from individual patients have created a great opportunity and a new need to incorporate individual patient model generation into clinical trials of experimental therapies. We can now use these models to test
therapeutics almost in real time — to identify what therapy the patient may or may not be likely to respond to and therefore, have real potential to change cancer care.
The Center for Patient Derived Models (CPDM) facilitates model availability and quality for Dana-Farber investigators and the wider cancer community.
CPDM supports researchers by generation, characterization, storage, and distribution of models of various types, including patient derived cell lines (PDCL), patient derived xenograft models (PDX), and fresh cell preparations.
To see the list of our cancer models, please register to access the CPDM Pan-Cancer Patient Derived Models cBioPortal database.
To request services, view a list of services, or generate a quote, contact us at email@example.com or 617-632-3641.
Find us on:LinkedInTwitter